[go: up one dir, main page]

CR9734A - Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6 - Google Patents

Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6

Info

Publication number
CR9734A
CR9734A CR9734A CR9734A CR9734A CR 9734 A CR9734 A CR 9734A CR 9734 A CR9734 A CR 9734A CR 9734 A CR9734 A CR 9734A CR 9734 A CR9734 A CR 9734A
Authority
CR
Costa Rica
Prior art keywords
sulfonylindazol
hydroxythyriptamine
ligands
derivatives
replaced
Prior art date
Application number
CR9734A
Other languages
English (en)
Inventor
Hassan Mahmoud Elokdah
Alexander Alexei Greenfield
Kevin Liu
Robert Emmett Mcdevitt
Geraldine Ruth Mcfarlane
Cristina Grosanu
Jeniffer Rebecca Lo
Yanfang Li
Albert Jean Robichaud
Ronald Charles Bernotas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9734A publication Critical patent/CR9734A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invencion suministra un compuesto de formula I y el uso de este para el tratamiento de un trastorno del sistema nervioso central relacionada con o afectado por el receptor 5-HT6.
CR9734A 2005-08-15 2008-02-15 Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6 CR9734A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70831505P 2005-08-15 2005-08-15

Publications (1)

Publication Number Publication Date
CR9734A true CR9734A (es) 2008-04-03

Family

ID=37668440

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9734A CR9734A (es) 2005-08-15 2008-02-15 Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6

Country Status (21)

Country Link
US (1) US7723329B2 (es)
EP (1) EP1931640A2 (es)
JP (1) JP5146766B2 (es)
KR (1) KR20080039994A (es)
CN (1) CN101282938A (es)
AR (1) AR057756A1 (es)
AU (1) AU2006280091A1 (es)
BR (1) BRPI0614343A2 (es)
CA (1) CA2619010C (es)
CR (1) CR9734A (es)
EC (1) ECSP088189A (es)
GT (1) GT200600376A (es)
IL (1) IL189476A0 (es)
NO (1) NO20080937L (es)
NZ (1) NZ565872A (es)
PE (1) PE20070354A1 (es)
RU (1) RU2429231C2 (es)
SA (1) SA06270314B1 (es)
TW (1) TW200740766A (es)
UA (1) UA94053C2 (es)
WO (1) WO2007021711A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
JP2009523734A (ja) * 2006-01-13 2009-06-25 ワイス ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール
BRPI0709817A2 (pt) * 2006-04-12 2011-07-26 Wyeth Corp composto da fàrmula i; mÉtodo para o tratamento de um distérbio do sistema nervoso central relacionado ou afetado pelo receptor de 5-ht6 em um paciente que necessita deste; composiÇço farmacÊutica; e processo para a preparaÇço de um composto da fàrmula i
WO2007120599A2 (en) * 2006-04-12 2007-10-25 Wyeth Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
US20090012308A1 (en) * 2007-06-13 2009-01-08 Wyeth Process for the manufacture of benzylsulfonylarenes
CN103102348B (zh) * 2011-11-14 2016-06-08 上海交通大学 噁二唑类化合物及其制备方法、药物组合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0004150A3 (en) 1997-11-04 2001-08-28 Pfizer Prod Inc Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
WO2001005758A2 (en) 1999-07-15 2001-01-25 Nps Allelix Corp. Indoles and indazoles for the treatment of migraine
BR0115102B1 (pt) 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
CN1281605C (zh) 2000-12-22 2006-10-25 惠氏公司 作为5－羟色胺－6配基的杂环基－吲唑或氮杂吲唑化合物
CN1492863A (zh) 2000-12-22 2004-04-28 作为5-羟色胺-6配基的杂环基烷基-吲哚或氮杂吲哚化合物
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US6815456B2 (en) 2001-04-20 2004-11-09 Wyeth Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
PL366639A1 (en) 2001-04-20 2005-02-07 Wyeth Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
YU96103A (sh) * 2001-06-07 2006-08-17 F.Hoffmann-La Roche Ag. Novi derivati indola sa afinitetom za 5-ht6 receptor
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
US7943639B2 (en) 2002-06-20 2011-05-17 Proximagen Limited Compounds
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
EP1556037B1 (en) * 2002-10-18 2006-11-02 F. Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
NZ539950A (en) * 2002-12-03 2007-05-31 Hoffmann La Roche Aminoalkoxyindoles as 5-HT6-receptor ligands for the treatment of CNS-disorders
BRPI0407253A (pt) * 2003-02-14 2006-01-31 Wyeth Corp Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
JP2006517966A (ja) 2003-02-14 2006-08-03 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのヘテロサイクリル−３−スルホニルアザインドールまたは−アザインダゾール誘導体
CA2557268A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
BRPI0614341A2 (pt) 2005-08-15 2011-03-29 Wyeth Corp composto; método para o tratamento de um distúrbio do sistema nervoso central relacionado com o receptor de 5-ht6 ou afetado por ele em um paciente que deste necessite; composição farmacêutica; e processo

Also Published As

Publication number Publication date
SA06270314B1 (ar) 2011-07-20
AR057756A1 (es) 2007-12-19
TW200740766A (en) 2007-11-01
JP2009504739A (ja) 2009-02-05
UA94053C2 (ru) 2011-04-11
ECSP088189A (es) 2008-04-28
GT200600376A (es) 2007-03-29
IL189476A0 (en) 2008-08-07
CA2619010C (en) 2013-10-01
WO2007021711A2 (en) 2007-02-22
WO2007021711A3 (en) 2007-05-03
NZ565872A (en) 2011-06-30
PE20070354A1 (es) 2007-04-04
AU2006280091A1 (en) 2007-02-22
KR20080039994A (ko) 2008-05-07
NO20080937L (no) 2008-04-30
RU2008105807A (ru) 2009-09-27
BRPI0614343A2 (pt) 2011-03-22
CA2619010A1 (en) 2007-02-22
US20070037802A1 (en) 2007-02-15
JP5146766B2 (ja) 2013-02-20
RU2429231C2 (ru) 2011-09-20
CN101282938A (zh) 2008-10-08
US7723329B2 (en) 2010-05-25
EP1931640A2 (en) 2008-06-18

Similar Documents

Publication Publication Date Title
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
PA8795601A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
ECSP10010025A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CO6640285A2 (es) 5-alquinil-pirimidinas
ECSP099553A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides
CO6341625A2 (es) Derivados de indol como agentes anticáncer
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
ECSP11011108A (es) Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
GT200600081A (es) Derivados de acetilenno
CO6390059A2 (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
ME00582A (en) Tricyclic compound and pharmaceutical use thereof
CR10474A (es) Derivados de benzozazol y benzotiazol como ligandos de 5-hidroxitriptamina-6
DOP2007000121A (es) Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para su preparación, medicamentos que comprenden estos compuestos y su uso
CR10339A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
PA8780701A1 (es) "aminoazaciclil-3-sulfonilindazoles como ligandos de 5-hidroxytryptamine-6"
CU20100045A7 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
CU20100047A7 (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3
UY32294A (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)